Biomarkers for Alzheimer's Disease Summit: Boston, July | Risk-free booking
July 14 - 16, 2020 - MA USWorld CNS | Hanson Wade
info@hansonwade.com
Phone:+1 6174554188
The inaugural Biomarkers for Alzheimer’s Disease Summit is the industry’s only forum dedicated to solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease, that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement. [N.b. COVID-19 risk-free registration policy applies**] With an emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this meeting delves into blood-based biomarkers, neuroinflammatory markers, NFL, microglial activation, exosomes and CSF synaptic biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s. Join drug developers and academics at the Biomarkers for Alzheimer’s Disease Summit. This is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships. **In light of the current COVID-19 situation, a risk-free booking policy applies so that you can register with peace of mind if the meeting cannot run due to COVID-19. Check out the website for full details.